Literature DB >> 25744944

Environmental factors in multiple sclerosis.

Vasiliki Pantazou1, Myriam Schluep1, Renaud Du Pasquier2.   

Abstract

Although multiple sclerosis (MS) is recognized as a disorder involving the immune system, the interplay of environmental factors and individual genetic susceptibility seems to influence MS onset and clinical expression, as well as therapeutic responsiveness. Multiple human epidemiological and animal model studies have evaluated the effect of different environmental factors, such as viral infections, vitamin intake, sun exposure, or still dietary and life habits on MS prevalence. Previous Epstein-Barr virus infection, especially if this infection occurs in late childhood, and lack of vitamin D (VitD) currently appear to be the most robust environmental factors for the risk of MS, at least from an epidemiological standpoint. Ultraviolet radiation (UVR) activates VitD production but there are also some elements supporting the fact that insufficient UVR exposure during childhood may represent a VitD-independent risk factor of MS development, as well as negative effect on the clinical and radiological course of MS. Recently, there has been a growing interest in the gut-brain axis, a bidirectional neuro-hormonal communication system between the intestinal microbiota and the central nervous system (CNS). Indeed, components of the intestinal microbiota may be pro-inflammatory, promote the migration of immune cells into the CNS, and thus be a key parameter for the development of autoimmune disorders such as MS. Interestingly most environmental factors seem to play a role during childhood. Thus, if childhood is the most fragile period to develop MS later in life, preventive measures should be applied early in life. For example, adopting a diet enriched in VitD, playing outdoor and avoiding passive smoking would be extremely simple measures of primary prevention for public health strategies. However, these hypotheses need to be confirmed by prospective evaluations, which are obviously difficult to conduct. In addition, it remains to be determined whether and how VitD supplementation in adult life would be useful in alleviating the course of MS, once this disease has already started. A better knowledge of the influence of various environmental stimuli on MS risk and course would certainly allow the development of add-on therapies or measures in parallel to the immunotherapies currently used in MS.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25744944     DOI: 10.1016/j.lpm.2015.01.001

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  9 in total

Review 1.  Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.

Authors:  Lei Yang; Dewei Tan; Hua Piao
Journal:  Neurochem Res       Date:  2016-04-21       Impact factor: 3.996

2.  Increasing incidence of multiple sclerosis among women in Buenos Aires: a 22 year health maintenance organization based study.

Authors:  E Cristiano; L Patrucco; J Miguez; D Giunta; J Peroni; J I Rojas
Journal:  Neurol Sci       Date:  2016-06-23       Impact factor: 3.307

3.  Cerebrospinal Fluid in a Small Cohort of Patients with Multiple Sclerosis Was Generally Free of Microbial DNA.

Authors:  Juan Jovel; Sandra O'keefe; Jordan Patterson; Michael Bording-Jorgensen; Weiwei Wang; Andrew L Mason; Kenneth G Warren; Gane Ka-Shu Wong
Journal:  Front Cell Infect Microbiol       Date:  2017-01-06       Impact factor: 5.293

Review 4.  Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives.

Authors:  Patricia K Coyle
Journal:  Mult Scler Int       Date:  2017-07-19

Review 5.  Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?

Authors:  Monika Adamczyk-Sowa; Aldona Medrek; Paulina Madej; Wirginia Michlicka; Pawel Dobrakowski
Journal:  J Immunol Res       Date:  2017-02-20       Impact factor: 4.818

6.  Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls.

Authors:  Selma Tekin; Levent Sinan Bir; Esin Avci; Hande Şenol; Işık Tekin; Ufuk Çınkır
Journal:  Cureus       Date:  2022-07-18

7.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

Review 8.  Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.

Authors:  Juan Xiao; Rongbing Yang; Sangita Biswas; Xin Qin; Min Zhang; Wenbin Deng
Journal:  Int J Mol Sci       Date:  2015-04-24       Impact factor: 5.923

9.  Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis.

Authors:  Roberto Bergamaschi; Livio Tronconi; Daniele Bosone; Antonella Mastretti; Laura Jommi; Marco Andrè Bassano; Renato Turrini; Sara Benati; Marco Volpe; Jean Marie Franzini; Silvia Allodi; Giulia Mallucci
Journal:  Neurol Sci       Date:  2021-06-15       Impact factor: 3.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.